Instruction for use: Actrapid MC

ATX Code A10AB03 Pork insulin

Active substance Insulin soluble [pork monocomponent]

Pharmacological group

Insulins

Nosological classification (ICD-10)

E10 Insulin-dependent diabetes mellitus

Decompensation of carbohydrate metabolism, Diabetes mellitus, Diabetes insulin sugar, Diabetes mellitus type 1, Diabetic ketoacidosis, Insulin-dependent diabetes, Insulin-dependent diabetes mellitus, Coma hyperosmolar non-ketoacidotic, Labile form of diabetes mellitus, Violation of carbohydrate metabolism, Type 1 diabetes mellitus, Type I diabetes mellitus, Insulin-dependent diabetes mellitus, Type 1 diabetes mellitus

E11 Non-insulin-dependent diabetes mellitus

Acetonuric diabetes, Decompensation of carbohydrate metabolism, Diabetes insulin-independent sugar, Diabetes sugar type 2, Type 2 Diabetes, Non-insulin-dependent diabetes, Non-insulin dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Insulin resistance, Insulin resistant diabetes mellitus, Coma lactobacillus diabetic, Violation of carbohydrate metabolism, Type 2 diabetes mellitus, Diabetes mellitus type II, Diabetes mellitus in adulthood, Diabetes mellitus in old age, Diabetes insulin-independent, Diabetes mellitus type 2, Sugar insulin-independent diabetes type II

Composition and form of release

1 ml solution for injection contains monocomponent pork insulin 40 or 100 IU; In bottles of 10 ml, in the box 1 bottle.

Characteristic

Neutral monocomponent pork insulin of short action.

pharmachologic effect

Pharmacological action - hypoglycemic.

Interacts with a specific receptor of the plasma membrane and penetrates into the cell, which activates the phosphorylation of cellular proteins, stimulates glycogen synthase, pyruvate dehydrogenase, hexokinase, inhibits fat lipase and lipoprotein lipase. In combination with a specific receptor facilitates the penetration of glucose into cells, enhances its assimilation by tissues and promotes conversion into glycogen. Increases the glycogen reserve in muscles, stimulates the synthesis of peptides.

Clinical Pharmacology

The effect develops 30 minutes after the SC administration, reaches a maximum after 1-3 hours and lasts 8 hours.

Indications

Diabetes mellitus type I, diabetes mellitus type II (with resistance to guanidine derivatives and sulfonylureas, intercurrent diseases, operations and in the post-operation period, during pregnancy).

Contraindications

Hypoglycemia, insulinoma.

Side effects

Hypoglycemia (up to coma), lipodystrophy (with prolonged use), allergic reactions (skin rash, laryngeal edema, extremely rarely - angioedema, anaphylactic shock).

Interaction

MAO inhibitors, non-selective beta-blockers, ACE inhibitors, salicylates, anabolic steroids, alcohol - increase, oral contraceptives, corticosteroids, thyroid hormones, thiazide diuretics, sympathomimetics - weaken the hypoglycemic effect.

Dosing and Administration

P / to, in / in (intravenously), in / m (intramuscularly). The dose is determined individually. At a daily dose exceeding 0.6 units (unit of action) / kg, the drug should be administered as two or more injections at different locations.

Overdose

Symptoms: development of hypoglycemia (cold sweat, palpitation, tremor, hunger, excitement, irritability, pallor, headache, drowsiness, movement uncertainty, speech and vision impairment, depression). Severe hypoglycemia can lead to temporary or permanent impairment of brain function, coma and death.

Treatment: sugar or glucose solution inside (if the patient is conscious), sc, v / m, or / in - glucagon or IV glucose.

Precautionary measures

It is not recommended to use in insulin dosers because of the possibility of precipitation in some catheters.

storage Conditions

At a temperature of 2-8 ° C (do not freeze).

Keep out of the reach of children.

Shelf life

2.5 years.

Do not use after the expiry date printed on the package.